Literature DB >> 20653051

Monoclonal antibody aggregation intermediates visualized by atomic force microscopy.

Hanjoo Lee1, Marc Kirchmeier, Henryk Mach.   

Abstract

Ubiquitous but highly variable processes of therapeutic protein aggregation remain poorly characterized, especially in the context of common infusion reactions and clinical immunogenicity. Among the numerous challenges is the characterization of intermediate steps that lead to the appearance of precipitates. Although the biophysical methods for elucidation of secondary and tertiary structures as well as overall size distribution are typically well established in the development laboratories, the use of molecular scale imaging techniques is still relatively rare due to low throughput and technical complexity. In this work, we present the use of atomic force microscopy to examine morphology of monoclonal antibody aggregates. Despite varying in primary structure as a result of different complementarity defining regions, most antibodies studied exhibited a similar aggregation intermediate consisting of several monomers. However, the manner of subsequent condensation of these oligomers appeared to differ between the antibodies, suggesting stability-dependent mechanisms.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20653051     DOI: 10.1002/jps.22279

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  5 in total

1.  Issues and challenges of subvisible and submicron particulate analysis in protein solutions.

Authors:  Thomas M Scherer; Stephenie Leung; Laura Owyang; Steven J Shire
Journal:  AAPS J       Date:  2012-03-06       Impact factor: 4.009

Review 2.  Protein particulate detection issues in biotherapeutics development--current status.

Authors:  Tapan K Das
Journal:  AAPS PharmSciTech       Date:  2012-05-08       Impact factor: 3.246

3.  Understanding the relevance of local conformational stability and dynamics to the aggregation propensity of an IgG1 and IgG2 monoclonal antibodies.

Authors:  Santosh V Thakkar; Neha Sahni; Sangeeta B Joshi; Bruce A Kerwin; Feng He; David B Volkin; C Russell Middaugh
Journal:  Protein Sci       Date:  2013-08-19       Impact factor: 6.725

Review 4.  Advanced protein formulations.

Authors:  Wei Wang
Journal:  Protein Sci       Date:  2015-05-01       Impact factor: 6.725

Review 5.  Therapeutic protein aggregation: mechanisms, design, and control.

Authors:  Christopher J Roberts
Journal:  Trends Biotechnol       Date:  2014-06-04       Impact factor: 19.536

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.